Company intelligence / Profile preview

Glyconics

Norwich, England, United Kingdomglyconics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Glyconics has developed a proprietary handheld infrared spectroscopy device for rapid, non-invasive diagnosis and monitoring of chronic conditions such as COPD and diabetes. The technology has been validated on over 500 samples for COPD signatures, with ongoing validation for exacerbation markers. A feasibility study in the Democratic Republic of Congo explored low-cost diabetic screening. The company is preparing to obtain CE Marking and move into its next clinical phase

Therapeutic areas: PulmonologyEndocrinology
Modalities: DeviceDiagnostic device (Infrared spectroscopy-based)
Industry: Metabolite Diagnostics

Partnerships

Spectrolytic (manufacturing agreement for handheld devices)University of Leicester / Dr Pratik Choudhary collaboration on clinical studies

Beyond the preview

Go deeper on Glyconics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glyconics.

Explore the full profile